Comparator Risk Before JCA: Where Value Is Lost Before the Dossier Exists

For pharma and biotech companies headquartered in the US, the European Union (EU) is often the next big market after FDA approval. Under the EU Joint Clinical Assessment, part of the EU Health Technology Assessment (HTA) Regulation, comparator considerations become clear only after key evidence is available. A pivotal program based on a US standard of care may find a different set of comparators in the EU. When that point is reached, relevant studies in the comparator network may differ in populations, endpoints, follow-up, and effect modifiers. This eventually limits the extent of comparison and weakens the payer evidence base. 

Join our webinar on “Comparator Risk Before JCA: Where Value Is Lost Before the Dossier Exists,” where we look at why comparator risk emerges well before dossier work begins. We treat it as a methodological issue, an early evidence strategy, and a Joint Clinical Assessment (JCA) readiness issue. The session covers how PICO assumptions shape what later becomes decision-relevant evidence, and why available data may still fail to support a credible indirect comparison when HTA and downstream payer decisions are made. 

Key Points to Be Addressed 

• JCA Relevance for US Pharma: Why the JCA matters for oncology and advanced therapy submissions, along with the gradual inclusion of orphan drugs and all centrally authorized products in phases. 

• Early Comparator Risk: Why comparator expectations are only become visible once significant evidence has been gathered and resources spent, before the dossier even exists. 

• US to EU Comparator Gaps: Identify the scenarios where the US standard of care and FDA endpoints are not aligned to EU member state comparator requirements. 

• PICO Assumptions: How the early choices about populations, interventions, comparators, and outcomes shape the evidence that later becomes relevant to JCA decision-making. 

• Comparator Network Mapping: Mapping out the differences in populations, endpoints, follow-up, and effect modifiers in relevant studies before these differences limit comparability. 

• Indirect Comparison Credibility: Why available evidence may still fail to support a credible indirect treatment comparison at the HTA stage. 

• Downstream Payer Impact: It involves analyzing how the gaps at JCA translate into HTA and payer evaluations across member states. 

• Early JCA Readiness: This includes a step-by-step approach for thoroughly testing comparator assumptions and evidential schemes before pivotal design is defined. 

Who Should Attend? 

This webinar is ideal for pharma and biotech professionals across market access, HEOR, evidence generation, clinical development, regulatory affairs, and global HTA strategy, especially teams planning EU launches or preparing for JCA submissions. 

Don’t wait for the dossier to expose comparator gaps. Address them while evidence strategy can still change the outcome. 

Secure your spot by filling out the registration form!